Literature DB >> 6981121

Useful laboratory measurements in the management of systemic lupus erythematosus.

W J Morrow, D A Isenberg, A Todd-Pokropek, H F Parry, M L Snaith.   

Abstract

Thirty-five patients with systemic lupus erythematosus (SLE) have been monitored clinically and serologically for up to three and a half years. The data collected was analysed by computer using the Statistical Package for the Social Sciences Program. The patients were categorized into severely active, moderately active and inactive disease groups and associations between clinical state and laboratory tests were sought. No single test was found to distinguish, reliably, the clinical groups but levels of circulating immune complexes (by polyethylene glycol precipitation), platelet count and ESR were shown to distinguish inactive from active disease (p less than 0.05). Severely active disease was distinguished from the less active forms by circulating immune complex levels (Clq solid phase assay) double-stranded DNA binding, lymphocyte count, and CH50 estimations (p less than 0.05). Tests were found to differ considerably in their ability to reflect disease activity when patients were separated into sub-groups according to the major clinical features (eg. arthralgia, renal disease and vasculitic rash). However, those patients with cerebral manifestations and thrombocytopenia proved to be the most difficult to assess. Discriminant function analysis showed that a maximum of 44 per cent of cases could be correctly classified into their clinical grades when combinations of four out of five laboratory tests were used. These results emphasise the continuing need for better tests to monitor the course of SLE.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6981121

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  33 in total

Review 1.  Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future.

Authors:  Chau-Ching Liu; Joseph M Ahearn; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

2.  Relation between antinuclear antibodies and the autoimmune rheumatic diseases and disease type and activity in systemic lupus erythematosus using a variety of cultured cell lines.

Authors:  J Sequi; I Leigh; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1991-03       Impact factor: 19.103

3.  Disease activity in systemic lupus erythematosus related to a range of antibodies binding DNA and synthetic polynucleotides.

Authors:  D A Isenberg; C Dudeney; W Williams; A Todd-Pokropek; B D Stollar
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

4.  Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.

Authors:  G Senaldi; V A Makinde; D Vergani; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1988-11       Impact factor: 19.103

5.  Assessment of class-specific antibodies against denatured DNA in patients with systemic lupus erythematosus.

Authors:  M Gripenberg; M Leirisalo; E Johansson; G Gripenberg
Journal:  J Clin Immunol       Date:  1985-09       Impact factor: 8.317

6.  Effect of high-dose methylprednisolone therapy on phagocyte function in systemic lupus erythematosus.

Authors:  S H Boghossian; D A Isenberg; G Wright; M L Snaith; A W Segal
Journal:  Ann Rheum Dis       Date:  1984-08       Impact factor: 19.103

7.  Anti-DNA antibodies of IgA class in patients with systemic lupus erythematosus.

Authors:  M Gripenberg; T Helve
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

8.  C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus.

Authors:  G Wild; J Watkins; A M Ward; P Hughes; A Hume; N R Rowell
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

9.  Enzyme-linked immunosorbent assays for antibodies to poly(A), poly dAT and histones: possibly useful tools for the evaluation of prognosis and disease activity in systemic lupus erythematosus.

Authors:  T Helve; M Gripenberg; P Kurki; A M Teppo; O Wegelius
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

10.  A long-term immunological study of childhood onset systemic lupus erythematosus.

Authors:  C K Ting; K H Hsieh
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.